Transcranial direct current stimulation is safe and effective in autoimmune myopathies: a randomised, double-blind, sham-controlled trial
Authors' conclusion
This study evidences the safety of tDCS, as well as its potential efficacy in improving muscle strength and function in SAMs patients.
Study context
- Population
- Patients with systemic autoimmune myopathies (SAMs)2 sham withdrew
- Participants
- 20 patients
- Comparison
- Active transcranial direct current stimulation (tDCS) vs sham tDCS
Methodological detailsprospective, sham-controlled, double-blind
- Prospective
- Sham-controlled
- Double-blind
Primary result
As reported in the abstract
Efficacy: SF-36, timed up-and-go test, peak torque
- Active tDCS: physical aspects of SF-36 at week 8, mean and better timed up-and-go test at each evaluation, peak torque of stimulated inferior limb extension improved significantly
- p<0.05
- Emotional aspect of SF-36 decreased only in active tDCS
- p<0.001
Safety
- Adherence to protocol
- 100%
- No serious adverse event reported, including disease relapses
Original publication
Transcranial direct current stimulation is safe and effective in autoimmune myopathies: a randomised, double-blind, sham-controlled trial. Clin Exp Rheumatol. Published 23 November 2021. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →